ArticleVirus research2026
QT interval prolongation and its related factors before and after receiving lopinavir-ritonavir in the COVID-19 era: a historical cohort study.
Article in Virus research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A historical cohort study in southern Iran investigated the effect of lopinavir-ritonavir treatment, with or without azithromycin and/or hydroxychloroquine, on QT interval prolongation in 500 confirmed COVID-19 patients. The outcomes showed a notable increase in the mean corrected QT interval post-treatment, specifically from 415.75±46.848 ms to 437.91±50.455 ms. QTc prolongation was observed only in patients receiving lopinavir-ritonavir monotherapy who also presented with cardiovascular conditions, angina pectoris, or hypomagnesemia, whereas those receiving concomitant therapy with azithromycin or hydroxychloroquine did not exhibit this effect. Other than one-third of patients with comorbidities or additional QT-prolonging drugs, aside from hypertension and obesity, had clinically the same potential of QT prolongation, and only 10.6% of patients had the problem. The work stresses the significance of careful monitoring of cardiac health, especially for those patients who have electrolyte imbalances and cardiovascular diseases as underlying diseases when they use lopinavir-ritonavir with other QT-prolonging medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.